Nhu Ngoc Le, Tran Quoc Bao Tran, John McClure, Dipender Gill, Sandosh Padmanabhan
{"title":"Emerging Antihypertensive Therapies and Cardiovascular, Kidney and Metabolic Outcomes: A Mendelian Randomisation Study.","authors":"Nhu Ngoc Le, Tran Quoc Bao Tran, John McClure, Dipender Gill, Sandosh Padmanabhan","doi":"10.1093/ehjcvp/pvaf015","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Emerging antihypertensive drug classes offer new opportunities to manage hypertension, however, their long-term effects on cardiovascular, kidney and metabolic (CKM) outcomes remain to be elucidated. This study aims to explore the effects of phosphodiesterase type 5 inhibitors (PDE5i), soluble guanylate cyclase stimulators (sGCs), endothelin receptor antagonists (ERA), and angiotensinogen inhibitors (AGTi) on a range of CKM outcomes.</p><p><strong>Methods and results: </strong>Mendelian randomisation (MR), summary-based MR (SMR), and colocalisation analyses were applied to assess the drug effect on coronary artery disease (CAD), myocardial infarction (MI), ischemic stroke, atrial fibrillation (AF), heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). Genetic association and gene expression summary data were obtained from the largest European-ancestry genome-wide association studies (GWAS) and the Genotype-Tissue Expression (GTEx) version 8 for 29 tissues relevant to the outcomes' pathophysiology.Genetically predicted systolic blood pressure (SBP) reduction was associated with reduced risks of all outcomes. PDE5i was associated with reduced risks of CAD (OR per 10-mmHg decrease in SBP: 0.348[95% CI: 0.199-0.607]) and ischemic stroke (0.588[0.453-0.763]). sGCs showed protective effects against CAD (0.332[0.236-0.469]), MI (0.238[0.168-0.337]), and CKD (0.55[0.398-0.761]). ERA and AGTi showed protective effects against CAD and ischemic stroke. SMR and colocalisation supported the association of gene expression levels of GUCY1A3 and PDE5A with CAD and MI risk.</p><p><strong>Conclusion: </strong>Our study highlights the potential of PDE5i, sGCs, ERA, and AGTi in reducing cardiovascular and renal risks. These findings underscore the necessity for targeted clinical trials to validate the efficacy and safety of these therapies.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvaf015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Emerging antihypertensive drug classes offer new opportunities to manage hypertension, however, their long-term effects on cardiovascular, kidney and metabolic (CKM) outcomes remain to be elucidated. This study aims to explore the effects of phosphodiesterase type 5 inhibitors (PDE5i), soluble guanylate cyclase stimulators (sGCs), endothelin receptor antagonists (ERA), and angiotensinogen inhibitors (AGTi) on a range of CKM outcomes.
Methods and results: Mendelian randomisation (MR), summary-based MR (SMR), and colocalisation analyses were applied to assess the drug effect on coronary artery disease (CAD), myocardial infarction (MI), ischemic stroke, atrial fibrillation (AF), heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). Genetic association and gene expression summary data were obtained from the largest European-ancestry genome-wide association studies (GWAS) and the Genotype-Tissue Expression (GTEx) version 8 for 29 tissues relevant to the outcomes' pathophysiology.Genetically predicted systolic blood pressure (SBP) reduction was associated with reduced risks of all outcomes. PDE5i was associated with reduced risks of CAD (OR per 10-mmHg decrease in SBP: 0.348[95% CI: 0.199-0.607]) and ischemic stroke (0.588[0.453-0.763]). sGCs showed protective effects against CAD (0.332[0.236-0.469]), MI (0.238[0.168-0.337]), and CKD (0.55[0.398-0.761]). ERA and AGTi showed protective effects against CAD and ischemic stroke. SMR and colocalisation supported the association of gene expression levels of GUCY1A3 and PDE5A with CAD and MI risk.
Conclusion: Our study highlights the potential of PDE5i, sGCs, ERA, and AGTi in reducing cardiovascular and renal risks. These findings underscore the necessity for targeted clinical trials to validate the efficacy and safety of these therapies.
期刊介绍：
The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, peer-reviewed journal published in English, specifically dedicated to clinical cardiovascular pharmacology. EHJ-CVP publishes original articles focusing on clinical research involving both new and established drugs and methods, along with meta-analyses and topical reviews. The journal's primary aim is to enhance the pharmacological treatment of patients with cardiovascular disease by interpreting and integrating new scientific developments in this field.
While the emphasis is on clinical topics, EHJ-CVP also considers basic research articles from fields such as physiology and molecular biology that contribute to the understanding of cardiovascular drug therapy. These may include articles related to new drug development and evaluation, the physiological and pharmacological basis of drug action, metabolism, drug interactions, and side effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
